Key Points of the Report

• Mira Pharmaceuticals, Inc. (NASDAQ: MIRA) received a notice from Nasdaq on July 27, 2026, regarding non-compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
• The notice was triggered because the closing bid price of Mira’s common stock was below \$1.00 per share for 30 consecutive business days, ending July 24, 2026.
• This non-compliance is with Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least \$1.00 per share.
• The notice does not result in immediate delisting; Mira’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “MIRA” for now.
• The company has a period to regain compliance with the minimum bid price requirement.

Details and Implications for Shareholders

• Share Price Sensitivity:
  • The fact that Mira’s stock has closed below \$1.00 for 30 consecutive business days is a significant event that may impact investor confidence and could increase volatility in the stock price.
  • If Mira fails to regain compliance within the specified period, its shares may be subject to delisting from the Nasdaq Capital Market, which would likely have a material adverse effect on share liquidity and investor perception.
• Remediation Period:
  • Mira Pharmaceuticals has a grace period under Nasdaq rules to remedy the deficiency. If the company is unable to do so, Nasdaq will issue a formal delisting notice.
  • Should a delisting notice be received, Mira may appeal to a Nasdaq Hearings Panel. However, the company notes there is no assurance any such appeal would be successful.
• Company Response:
  • The company intends to actively monitor its closing bid price and consider implementing available options to regain compliance. These options could include corporate actions such as a reverse stock split or other measures aimed at increasing the stock price.
  • There is no guarantee that the company will be able to regain compliance with the minimum bid price requirement.
• Forward-Looking Statements:
  • This report contains forward-looking statements regarding Mira’s ability to regain compliance, the potential actions by Nasdaq, and the company’s plans to address the deficiency.
  • Risks cited include the possibility of not regaining compliance, not being granted relief by Nasdaq, and not meeting Nasdaq’s requirements even if relief is granted.
  • Shareholders are advised to review the company’s most recent filings with the SEC for a full discussion of risks and uncertainties.

Other Notable Information

• The company is classified as an emerging growth company under Rule 405 of the Securities Act of 1933.
• Mira has not elected to use the extended transition period for compliance with any new or revised financial accounting standards.
• There are no immediate changes to the company’s operations or its listing status as a result of this notice.

Potential Impact on Investors

This development is potentially price sensitive. The risk of delisting can negatively impact the stock’s attractiveness to institutional and retail investors, potentially increasing volatility and downward pressure on the share price. Investors should monitor further announcements from the company regarding any remedial actions or updates from Nasdaq.